orbofiban has been researched along with aspirin in 12 studies
| Studies (orbofiban) | Trials (orbofiban) | Recent Studies (post-2010) (orbofiban) | Studies (aspirin) | Trials (aspirin) | Recent Studies (post-2010) (aspirin) |
|---|---|---|---|---|---|
| 48 | 17 | 0 | 48,947 | 6,817 | 13,778 |
| Protein | Taxonomy | orbofiban (IC50) | aspirin (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 0.35 | |
| Integrin beta-3 | Homo sapiens (human) | 5 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.8252 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 1.375 | |
| Integrin alpha-IIb | Homo sapiens (human) | 5 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 2.271 | |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | 2.4 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 2.15 | |
| Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 0.3 | |
| 4-aminobutyrate aminotransferase, mitochondrial | Rattus norvegicus (Norway rat) | 2.4 | |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.35 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 2.4081 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 11 (91.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferguson, JJ | 1 |
| Asai, F; Naganuma, H; Ogawa, T; Sugidachi, A | 1 |
| Alexander, JC; Anders, RJ; Berink, P; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Langer, A; Lopez-Sendon, J; McCabe, CH; Skene, A; Toman, J; Wilcox, RG | 1 |
| McGuire, DK; Newby, LK | 1 |
| Bhatt, DL; Chew, DP; Sapp, S; Topol, EJ | 1 |
| Braunwald, E; Cannon, CP; Fitzgerald, A; Fitzgerald, DJ; O'Connor, FF; Shields, DC | 1 |
| Barbera, FA; Dorsam, RT; Feuerstein, GZ; Friedman, SM; Gibbs, S; Lauver, A; Savion, N; Varon, D; Wang, H; Wang, X | 1 |
| Bentley, J; Blatt, A; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Cotter, G; Kaluski, E; Krakover, R; Lewis, B; Marmor, A; McCabe, CH; Michowitz, Y; Milo, O; Reisin, L; Vered, Z; Zimlichman, R | 1 |
| Cannon, CP; Feske, SK; Murphy, S; Schwamm, LH; Smith, EE | 1 |
| Atar, S; Birnbaum, Y; Cannon, CP; Murphy, SA; Rosanio, S; Uretsky, BF | 1 |
| Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM | 1 |
| Alonso Castillejos, N; García Iglesias, R; Inglada-Galiana, L; Martín Gil, FJ; San Miguel Hernández, A | 1 |
2 review(s) available for orbofiban and aspirin
| Article | Year |
|---|---|
Oral platelet glycoprotein IIb/IIIa inhibition.
Topics: Alanine; Angina, Unstable; Aspirin; Benzamidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Myocardial Infarction; Oximes; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Syndrome; Treatment Outcome | 2000 |
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Topics: Administration, Oral; Alanine; Aspirin; Benzamidines; Clinical Trials, Phase III as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Humans; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Oximes; Piperidines; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic | 2001 |
5 trial(s) available for orbofiban and aspirin
| Article | Year |
|---|---|
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Topics: Administration, Oral; Alanine; Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heparin; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Stroke; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2000 |
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
Topics: Aged; Alanine; Angina, Unstable; Antigens, Human Platelet; Aspirin; Double-Blind Method; Female; Genetic Variation; Genotype; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Pyrrolidines | 2001 |
Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysi
Topics: Aged; Alanine; Aspirin; Cerebrovascular Disorders; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Multivariate Analysis; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Pyrrolidines; Regression Analysis; Risk Factors; Treatment Outcome | 2003 |
Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Proportional Hazards Models; Pyrrolidines; Risk Factors; Stroke; Syndrome; Thrombolytic Therapy | 2006 |
Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombocytopenia; Thrombosis | 2006 |
5 other study(ies) available for orbofiban and aspirin
| Article | Year |
|---|---|
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Monoclonal; Aspirin; Benzamidines; Biphenyl Compounds; Cardiology; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Disease; Dalteparin; Defibrillators, Implantable; Double-Blind Method; Enalapril; Endothelial Growth Factors; Fatty Acids, Omega-3; Guanidines; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Laser Therapy; Lymphokines; Metoprolol; Multicenter Studies as Topic; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pyrrolidines; Randomized Controlled Trials as Topic; Simvastatin; Sodium-Hydrogen Exchangers; Stents; Sulfones; Thrombolytic Therapy; Ticlopidine; Tissue Plasminogen Activator; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vitamin E | 1999 |
Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
Topics: Adenosine Diphosphate; Administration, Oral; Alanine; Animals; Arteriovenous Shunt, Surgical; Aspirin; beta-Alanine; Bleeding Time; Collagen; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Guinea Pigs; Hemostasis; Hypercholesterolemia; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombosis; Urea | 2000 |
Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
Topics: Abciximab; Alanine; Amidines; Analysis of Variance; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cell Aggregation; Dose-Response Relationship, Drug; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Isoxazoles; Peptides; Platelet Activation; Platelet Adhesiveness; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Rheology; Shear Strength; Temperature; Tirofiban; Tyrosine | 2002 |
Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial.
Topics: Acute Disease; Administration, Oral; Aged; Alanine; Anticoagulants; Aspirin; Coronary Disease; Female; Gastrointestinal Hemorrhage; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Patient Discharge; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Retrospective Studies; Risk Assessment; Severity of Illness Index; Syndrome | 2006 |
[Soluble CD40 ligand: a potential marker of cardiovascular risk].
Topics: Abciximab; Acute Coronary Syndrome; Alanine; Angina, Unstable; Animals; Antibodies, Monoclonal; Anticoagulants; Aspirin; Atherosclerosis; Biomarkers; Cardiovascular Diseases; CD40 Ligand; Chromosomes, Human, X; Clinical Trials as Topic; Disease Models, Animal; Female; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Mice; Platelet Activation; Platelet Aggregation Inhibitors; Prognosis; Pyrrolidines; Risk Factors; Thrombosis | 2007 |